Alzheimer's Lecanemab Treatment Up to 36 Months Supported by Extension Study
(MedPage Today) — SAN DIEGO — Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early Alzheimer’s disease, initial findings from the CLARITY AD open-label extension study…
Source link